Registration Number
0218U002074,
0116U000189
, R & D reports
Title
Develop technology treatment of bronchial asthma in children, depending on the pheno-genotypic characteristics of the organism
popup.stage_title
Head
Rechkina Olena Oleksandrivna,
Registration Date
12-01-2018
Organization
Institute of tuberculosis and pulmonology named by F. G. Yanovsky
popup.description2
Object: 136 children with bronchial asthma (BA). Aim - improving the efficiency of treatment of children with asthma, on the basis of new scientific evidence on the association of polymorphic variants of genes and the establishment of candidate genes that determine individual response to drugs are the basic treatment, the formation of pheno-genotypes of bronchial asthma in children and the development of the algorithm of differentiated selection schemes base therapy of pheno-genotypic differences. Methods - clinical, questionnaires, functional, immunological, molecular genetic, mathematics, statistics. The leading genotypes intergenetic and gene-factor interactions, which modify the response to treatment and increased the risk of uncontrolled asthma for 2-3 times were installed: genotypes - AT2R1_CC / AC, eNOS T-786C_CC and NAT C41T_TT; gene-gene associations - AT2R1_AC + eNOS T-786C_CC and AT2R1_CC + NAT C41T_TT; gene-factor associations - the phenotype of IgE-dependent BA with high levels of total IgE (> 400 IU/l) in the polymorphisms AC/CC presence of the gene AT2R1 in children under 12 years of age and the eNOS T-786C_CC genotype among older children. Phenotypes of partially controlled and uncontrolled asthma on indices of obstructive type ventilation disorders that are associated with certain genotypes: FVC, FEV1, MEF 75% with polymorphism of the ACE gene; FEV%, FEV / FVC%, MEF 25% with AT2R1 gene polymorphism; FEV1 / FVC, 25% MEF with the deletion genotype of the GSTM1 gene. A technology for determining the risk of developing severe uncontrolled asthma in children by the index of functional changes (IFC) and the Kerdo index (IK) was developed: at IFC > 3,09 (disruption of adaptive reserves) and IK < 1 (vagotonia), the risk is recognized as high, baseline therapy, reducing the time to achieve asthma control for 3-6 months in 70,0 % patients who had previously been inadequately treated and reduce the incidence of asthma exacerbations by 30,0 %. Sphere of application - pediatry, pulmonology, allergology
Product Description
popup.authors
Ільїнська Ірина Федорівна
Копосова Ірина Вікторівна
Костроміна Вікторія Павлівна
Кравцова Оксана Миколаївна
Матусевич Валентина Георгієвна
Мельник Катерина Олександрівна
Петішкіна Валерія Миколаївна
Промська Наталія Вікторівна
Речкіна Олена Олександрівна
Россоха Зоя Іванівна
Руденко Сегрій Миколайович
Стриж Віра Олександрівна
popup.nrat_date
2020-04-02
